TRCT
PYXS icon

Tower Research Capital (TRC)’s Pyxis Oncology PYXS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1K Sell
10,332
-478
-4% -$720 ﹤0.01% 3680
2025
Q4 		$12.4K Sell
10,810
-2,172
-17% -$7.66K ﹤0.01% 3481
2025
Q3 		$28.8K Sell
12,982
-1,675
-11% -$2.41K ﹤0.01% 2973
2025
Q2 		$16.1K Buy
14,657
+3,499
+31% +$3.94K ﹤0.01% 3795
2025
Q1 		$10.9K Buy
11,158
+3,720
+50% +$4.96K ﹤0.01% 3590
2024
Q4 		$11.6K Buy
7,438
+3,283
+79% +$9.47K ﹤0.01% 3693
2024
Q3 		$15.2K Buy
+4,155
New +$14.5K ﹤0.01% 3418
2024
Q2 		– Sell
-9,706
Closed -$41.3K – 5946
2024
Q1 		$41.3K Buy
9,706
+4,067
+72% +$17.1K ﹤0.01% 2411
2023
Q4 		$10.2K Buy
5,639
+3,656
+184% +$6.26K ﹤0.01% 4285
2023
Q3 		$3.95K Buy
+1,983
New +$4.59K ﹤0.01% 4939
2023
Q2 		– Sell
-10,866
Closed -$43K – 6298
2023
Q1 		$43K Buy
10,866
+4,688
+76% +$9.36K ﹤0.01% 2640
2022
Q4 		$8K Sell
6,178
-9,558
-61% -$14.3K ﹤0.01% 4442
2022
Q3 		$31K Buy
15,736
+12,676
+414% +$33.1K ﹤0.01% 3583
2022
Q2 		$7K Buy
3,060
+437
+17% +$1.16K ﹤0.01% 4820
2022
Q1 		$11K Buy
2,623
+1,960
+296% +$14.3K ﹤0.01% 4202
2021
Q4 		$7K Buy
+663
New +$7.59K ﹤0.01% 4932

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s PYXS Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Pyxis Oncology (PYXS) stake by 4.4% in Q1 2026, selling an estimated $720 and leaving 10,332 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Tower Research Capital (TRC) first reported a position in PYXS in Q4 2021 and has held it in 16 quarters since. The position peaked at $43K in Q1 2023. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Tower Research Capital (TRC) held 10,332 shares of Pyxis Oncology worth $15.1K as of Q1 2026.
  • Tower Research Capital (TRC) sold 478 Pyxis Oncology shares in Q1 2026, an estimated $720.
  • Pyxis Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3680 holding.
  • Tower Research Capital (TRC) first reported a position in Pyxis Oncology in Q4 2021 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Pyxis Oncology position peaked at $43K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.